Novo Nordisk reported phase II results showing its dual amylin/GLP‑1 agonist amycretin produced a mean 14.5% body‑weight reduction in type 2 diabetes patients over 36 weeks with substantial HbA1c control, prompting the company to expand the program into pivotal diabetes trials. The mid‑stage readout also showed high rates of A1C <7% in treated participants. Novo said the results broaden amycretin’s positioning beyond obesity into diabetes care and will fuel Phase III planning. The data reinforce industry momentum for multi‑agonist metabolic agents and follow Novo’s recent regulatory activity around GLP‑1 products. For competitors and payors, amycretin’s profile will be evaluated for safety, durability and comparative effectiveness versus established GLP‑1s and dual agonists. Novo’s decision to accelerate into pivotal diabetes studies signals continued investment in next‑generation metabolic therapeutics and raises stakes for pricing and access discussions as the market evolves.